Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High – Should You Buy?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) reached a new 52-week high on Wednesday . The stock traded as high as $52.42 and last traded at $52.1040, with a volume of 97765 shares traded. The stock had previously closed at $51.73.

Analysts Set New Price Targets

Several equities analysts have commented on ELVN shares. Mizuho increased their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Guggenheim assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price for the company. JonesTrading increased their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Finally, The Goldman Sachs Group boosted their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $69.17.

Enliven Therapeutics Price Performance

The business’s 50-day moving average price is $44.15 and its 200-day moving average price is $35.84. The firm has a market capitalization of $3.10 billion, a PE ratio of -30.45 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Equities analysts forecast that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the transaction, the director directly owned 51,884 shares in the company, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. The trade was a 10.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 26,018 shares of company stock worth $1,113,888. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Commodore Capital LP lifted its stake in shares of Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after acquiring an additional 17,809 shares during the period. Vestal Point Capital LP lifted its position in Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the period. Polar Capital Holdings Plc boosted its holdings in Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after purchasing an additional 418,673 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Enliven Therapeutics by 9.1% in the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock valued at $16,214,000 after buying an additional 87,725 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.